Brinker Capital Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 342,902 shares of the biopharmaceutical company’s stock after buying an additional 5,958 shares during the quarter. Brinker Capital Inc.’s holdings in Pfizer were worth $13,435,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in PFE. TFO TDC LLC bought a new stake in Pfizer in the fourth quarter worth $37,000. Wealthcare Capital Management LLC lifted its position in Pfizer by 61.2% during the fourth quarter. Wealthcare Capital Management LLC now owns 1,069 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 406 shares during the period. Stonebridge Financial Planning Group LLC bought a new position in Pfizer during the fourth quarter valued at approximately $55,000. Cardinal Capital Management Inc. lifted its position in Pfizer by 45.0% during the fourth quarter. Cardinal Capital Management Inc. now owns 1,450 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 450 shares during the period. Finally, ICW Investment Advisors LLC bought a new position in Pfizer during the fourth quarter valued at approximately $58,000. 71.63% of the stock is currently owned by institutional investors.
Several research firms have weighed in on PFE. Mizuho reiterated a “buy” rating and issued a $42.00 price target on shares of Pfizer in a research report on Wednesday, March 18th. Barclays began coverage on shares of Pfizer in a research report on Thursday, February 27th. They issued an “equal weight” rating and a $36.00 price target on the stock. Standpoint Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, February 27th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $37.00 price target on shares of Pfizer in a research report on Tuesday, January 28th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a research report on Thursday, March 19th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Pfizer currently has a consensus rating of “Buy” and an average target price of $41.36.
In related news, major shareholder Pfizer Inc bought 312,500 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was bought at an average cost of $16.00 per share, with a total value of $5,000,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were bought at an average cost of $37.15 per share, with a total value of $37,150.00. Following the completion of the purchase, the director now directly owns 4,000 shares of the company’s stock, valued at approximately $148,600. The disclosure for this purchase can be found here. Corporate insiders own 0.08% of the company’s stock.
Shares of NYSE PFE traded up $1.10 during midday trading on Thursday, reaching $30.85. The stock had a trading volume of 6,623,557 shares, compared to its average volume of 47,605,496. The stock has a 50-day moving average of $34.45 and a 200-day moving average of $36.98. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.66 and a current ratio of 0.88. The company has a market capitalization of $164.76 billion, a price-to-earnings ratio of 10.75, a price-to-earnings-growth ratio of 2.39 and a beta of 0.69. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $44.56.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.57 by ($0.02). The firm had revenue of $12.69 billion during the quarter, compared to analysts’ expectations of $12.73 billion. Pfizer had a return on equity of 27.01% and a net margin of 31.44%. The business’s revenue for the quarter was down 9.2% on a year-over-year basis. During the same period last year, the company earned $0.64 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.8 EPS for the current fiscal year.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Why Invest in High-Yield Dividend Stocks?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.